SEC Tracker
Get the app

Rhythm Pharmaceuticals RYTM

Rhythm Pharmaceuticals reported Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Global IMCIVREE revenue of $92.1 million, up 29% sequentially
  2. More than 700 patient start forms for IMCIVREE in the U.S.
  3. Commercial launch of IMCIVREE in Japan for acquired HO
  4. Amended bivamelagon licensing agreement with LG Chem

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Rhythm Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Vaxcyte PCVX public float $3.7B, Jun 30, 2025
  2. Dynavax Technologies DVAX
  3. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  4. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
  5. Adma Biologics ADMA public float $4.2B, Jun 30, 2025